Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
News BriefGoogle told to pay $314M over cellular data in California class action suit
A jury in California last week said Google misused cellular data from people who owned smartphones powered by its Android software, and must pay users in the state roughly $314.6 million.
-
WebcastAug 7 | No Longer Optional: The Future of AI in TPRM
Don’t miss this opportunity to prepare your organization for the future of TPRM and stay ahead with AI as your second-in-command.